0001140361-25-006272.txt : 20250227 0001140361-25-006272.hdr.sgml : 20250227 20250227160115 ACCESSION NUMBER: 0001140361-25-006272 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240517 FILED AS OF DATE: 20250227 DATE AS OF CHANGE: 20250227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schwartz Jonathan David CENTRAL INDEX KEY: 0001726398 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36829 FILM NUMBER: 25678507 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET STREET 2: SUITE 1040 CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ROCKET PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001281895 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 350 FIFTH AVENUE STREET 2: SUITE 7530 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: 646-440-9100 MAIL ADDRESS: STREET 1: 350 FIFTH AVENUE STREET 2: SUITE 7530 CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: INOTEK PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20040226 4 1 form4.xml FORM 4 X0508 4 2024-05-17 0001281895 ROCKET PHARMACEUTICALS, INC. RCKT 0001726398 Schwartz Jonathan David C/O ROCKET PHARMACEUTICALS, INC. 9 CEDARBROOK DRIVE CRANBURY NJ 08512 true See Remarks false Common Stock 2024-05-17 4 S 0 2754 23.35 D 169659 D Common Stock 2024-08-16 4 S 0 2710 18.5 D 166949 D Common Stock 2024-11-21 4 S 0 3097 13.05 D 163852 D Common Stock 2025-02-25 4 S 0 6532 10.58 D 237638 D Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Inclusive of the acquisition of 80,318 RSUs that convert to common stock on a one-for-one basis, as reported on the Reporting Person's Form 4 filed on 02/13/2025. Chief Medical & Gene Therapy Officer /s/ Martin Wilson, as attorney-in-fact for Jonathan Schwartz 2025-02-27